Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Replimune Group ( (REPL)) ...

NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities ...

Brian W. Stone does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the ...

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the ...

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...

NEW YORK CITY, NY / ACCESS Newswire / July 29, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ:REPL) and ...

SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent ...

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price hit a new 52-week low on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays ...